References
- Bottomiey SS. Secondary iron overload disorders. Sem Hematol 1998;35:77-86.
- Tavill AS, Bacon BR. Hemochromatosis: iron metabolism and the iron overload syndromes. In: Hepatology: a textbook of liver disease. Vol 2. ΨB. Sauders Co., 1990.
- Edwards CQ, Griffen LM,Goldgar D,et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-62.
- McLaren CE, Gordeuk VR, Looker AC, et al. Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood 1995;86:2021-7.
- Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nature Genetics 1996; 13:399-408.
- Martinez PA, Biron C, Blanc F, et al. Compound heterozygotes for hemochromatosis gene mutations: may they help understand the pathophysiology of the disease? Blood Cells, Molecules, and Diseases 1997;23:269-76.
- Jouanoile AM, Gandon G, Jezequel Ę et al. Haemochromatosis and HLA-H (correspondence). Nature Genetics 1996;14:251-2.
- Jazwinsa .EC, Cullen LM, Busfields Ę et al. Haemochromatosis and HLA-A (correspondence). Nature Genetics 1996;14:249-51.
- Conrad ME, Umbreit JN. A concise review: iron absorption—the mucin-mobilferrin-integrin pathway. A competitive pathway for metal absorption. Am J Hematol 1993;42:67-73.
- Lombard M, Chua E, O’Toole R Regulation of intestinal non-haem iron absorption. Gut 1997;40:435-9.
- Rothenberg BE, Voland JR. Beta-2 knockout mice develop parenchymal iron overload: a putative role for class I genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci 1996; 93:1529-34.
- Santos M, Schilham MW, Rademakers L, et al. Defective iron homeostasis in beta-2 microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996;184:1975-85.
- Parkkila S, Waheed A, Britton RS, et al. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci 1997;94:2534-9.
- Feder JN, Tsuchihashi Z, Irrinki A, et al. The hemochromatosis founder mutation in HLA-H disrupts beta-2 microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8.
- Waheed A, Parkkila S, Zhou XY, et al. Hereditary hemochromatosis: effects of C282Y and. H63D mutations on association with beta-2-microg?obulin, intracellular processing, and cell surface expression of the HEE protein in COS-7 cells. Proc Natl Acad Sci 1997;94:12384-9.
- Zhou XY,Tomatsu S, Sly WS, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci 1998;95:2492-7.
- Bothwell TH, MacPhail AP Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Sem Hematol 1998;35:55-71.
- Sullivan JL. Iron versus cholesterol—perspectives on the iron and heart disease debate. J Clin Epidemiol 1996;49:1345-52.
- Salonen JT, Nyyssonen K, Heikki K, et al. High-stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992;86:803-11.
- Meyers DG, Strickland D, Maloley PA, et al. Possible association of a reduction in cardiovascular events with blood donation. Heart !997;78:l88-93·
- McCord JM. Effects of positive iron status at the cellular level. Nutrition Rev 1996;54:85-8.
- Corti M-C, Gaziano M, Hennekens CH. Iron status and risk of cardiovascular disease. Amt Epidemiol 1997;7:62-8.
- Tuomainen P-Ę Salonen R, Nyyssonen K, Salonen JT. Cohort study of relation between donating blood and risk of myocardial, infarction in 2ĉ82 men in eastern Finland. BMJ 1997;314:793-4.
- Miller M, Hutchins GM. Hemochromatosis, multiorgan hemosiderosis, and coronary artery disease. JAMA 1994;272:231-3.
- Sempos CT, Looker AC, Gillum RĘ Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994;330:1119-24.
- Cartwright GE, Edwards CQ, Dravitz K, et ai. Hereditary hemochromatosis: phenotypic expression of the disease. N Engl J of Med 1979;3Ol: 1.75-9.
- Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 3O-year database. Gastroenterology 1995; 109:177-88.
- Burke W; Thomson E, Khoury MJ, et al. Genetic testing for hereditary hemochromatosis and its implications. JAMA l998;280:172-8.
- Edwards CQ, Griffon LS, Ajoika RS, Kushner JP Screening for hemochromatosis: phenotype versus genotype. Sem Hαtnatol 1998;35:72-6.
- Levstik M, Adams PC. Eligibility and exclusion of hemochromatosis patients as voluntary blood donors. Can J Gastroenterology l998;!2:6l-3·
- 31- GriπdonA. Blood collection. In: McClatchey KD, ed. Clinical laboratory medicine. Baltimore, MD: Williams & Wilkins, 1994:1687.
- National Institutes of Health. Use of neocytes decrease frequency of transfusions to reduce iron overload. JAMA 1979;242:2669-70.
- Alter HJ, Holland PV, Purcell RH, et a?. Post-transfusion hepatitis after exclusion of commercial and hepatitis B antigen positive donors. Ann Intern Med 1972:77:691-9.
- Klein H, ed. Standards for blood banks and transfusion services. I7th ed. Bethesda, MD: American Association of Blood Banks, 1996.
- Williams AE,Thomson RA, Horton ĴA, Kleinman SH, Characterization of active blood donors who recently donated blood primarily to receive an HIV test. Transfusion 1995 (Suppl)35:42S.